Using Near-Infrared Light to Better Understand Peripheral Artery Disease
The University of Texas at Arlington · NCT07313410
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 120
- US sites recruiting
- 1
- Study start
- November 1, 2025
- Record last updated
- January 2, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this study is to better understand how blood flows and how oxygen is utilized in the lower limbs of people who suffer from peripheral artery disease. This study will also assess how these factors affect treatment outcomes.
Specific aims include
Aim 1: Utilize BB-NIR-DCS to differentiate PAD patients experiencing primary oxygen delivery limitations from those suffering from mitochondrial dysfunction.
Aim 2: Test the efficacy of BB-NIR-DCS at predicting individual responses to vascular intervention.
Conditions: Peripheral Artery Disease (PAD)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Cases, Aim 1
- 18 or older
- willing to participate under the conditions described in the informed consent form (ICF)
- eligible to sign the ICF
- established diagnosis of PAD confirmed by a physician
- able to comply with the study requirements
- Cases, Aim 2
- completed Aim 1
- Controls 1) asymptomatic, with no history or diagnosis of peripheral artery disease
Exclusion Criteria
- Cases, Aim 1
- Ankle-Brachial Index >0.9 or \<0.4
- isolated disease in aorta/iliac vessels
- unstable angina or myocardial infarction in past 12 months
- orthopedic or other physical limitations which would prevent data collection
- contraindications to MRI, including presence of a Pacemaker, presence of bone growth/ bone fusion stimulators, presence of tissue expander, presence of cochlear implants, unable to ambulate for 10 feet, receiving continuous Oxygen therapy, pregnancy, permanent Jewelry (screened using MRI safety screening form and verbal screening by MRI operator
- Cases, Aim 2
- unstable angina or myocardial infarction in past 12 months
- orthopedic or other physical limitations which would prevent data collection
- contraindications to MRI, including presence of a pacemaker, presence of bone growth/ bone fusion stimulators, presence of tissue expander, presence of cochlear implants, unable to ambulate for 10 feet, receiving continuous Oxygen therapy, pregnancy, permanent Jewelry (screened using MRI safety screening form and verbal screening by MRI operator).
- Controls 1) history of peripheral artery disease 2) overt cardiovascular disease (e.g. heart failure) 3) known pulmonary disease (excluding mild asthma) 4) current tobacco use 5) orthopedic or other physical limitations which would prevent data collection, 6) BP >150/90 mmHg at screening 7) contraindications to MRI, including presence of a pacemaker, presence of bone growth/ bone fusion stimulators, presence of tissue expander, presence of cochlear implants, unable to ambulate for 10 feet, receiving continuous Oxygen therapy, pregnancy, permanent Jewelry (screened using MRI safety screening form and verbal screening by MRI operator).
Recruiting US locations
University of Texas at Arlington
Arlington, TX 76010
Site contact: Rajvi Shah · 2147557
Study contacts (from the official record)
- Michael Nelson, PhD · 8175130383 · michael.nelson3@uta.edu
- Rajvi Shah, MPH · 2147557343 · rajvi.shah@uta.edu
Similar studies in Texas
All healthy volunteers studies in Texas →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of LY4355756 in Healthy Participants
Eli Lilly and Company
- Location
- Dallas, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- San Antonio, TX + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- San Antonio, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Radiprodil in Participants With Hepatic Impairment
GRIN Therapeutics, Inc.
- Location
- DeSoto, TX + 1 other US site
- Eligibility basics
- Ages 18–75